ArticleJCI insight2026

Selective SIK2/SIK3 inhibition reprograms pro- and antiinflammatory pathways in myeloid cells, improving autoimmune disease outcomes.

Steve De Vos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.